The Huntington’s Disease Regulatory Science Consortium was formed with the goal of improving the regulatory path for emerging therapies for Huntington’s disease. This global initiative will facilitate collaboration among biopharma/technology industry partners, academic institutions, government agencies, and patient-advocacy organizations.
The Huntington Study Group’s renowned annual event, HSG 2019: Navigating HD, will bring together more than 600 of the world’s leading Huntington disease (HD) researchers, health care providers, industry representatives, and members of the HD community to provide a forum for training and education in Huntington disease (HD) and for presentation of new research findings and treatments to the worldwide community,
The goal of the meeting is to bring together today’s worldwide leaders in the treatment of Alzheimer’s disease to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer’s disease treatments.
The 1st Spinocerebellar Ataxia (SCA) Global Conference proved an exciting time for the Ataxia community, with a goal to assemble a global consortium for clinical studies of the spinocerebellar ataxias, (SCAs).
IXICO sponsored the event and presented a poster: ''Development of a fully automated method for MRI volumetry in ataxia''
International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders.
As the industry continues to debate approaches to the long term solution to finding treatments in Alzheimer's disease, particularly following recent announcements of further late phase failures, IXICO is continuing in its work to support clinical research in these Therapeutic Areas through collaboration, partnership and innovation in technology that supports the increasing requirement for better data science.